Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449567 | 0.83 | MAPT (0.51) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL436856 | 0.78 | — | — | |
| SCHEMBL958545 | 0.76 | — | — | |
| SCHEMBL6363647 | 0.76 | — | — | |
| SCHEMBL24768947 | 0.75 | MAPT (0.44) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8723035 | 0.75 | MAPT (0.44) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL9089346 | 0.75 | MAPT (0.44) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4780449 | 0.74 | RAB9A (0.60) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL4824847 | 0.74 | GABRA5 (0.47) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL3999942 | 0.74 | GABRA5 (0.51) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453913-A4 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA INC (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | claimed |
| EP-1453913-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | Antex Pharma, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003062443-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA, INC. (US) | 2003-07-31 | — | — | WO | claimed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1453913-A4 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | disclosed |
| EP-1453913-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | Antex Pharma, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003062443-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | MAPT 3874/4885SMN1; SMN2 4852/4885RAB9A 4140/4885 |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | ALK, CYP11B2, ALKBH2 | MAPT 4130/4885SMN1; SMN2 3019/4885RAB9A 2607/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | MAPT 3874/4885SMN1; SMN2 4852/4885RAB9A 4140/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | MAPT 3874/4885SMN1; SMN2 4852/4885RAB9A 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.